Top 20 Cancer Therapy Brands Sales of targeted therapies overtake cytotoxics in 2006

Sales of the Top 20 cancer therapy brands in each of the seven major markets totaled $24.5 billion in 2006 and are forecast to grow at a CAGR of 6.6% to $45.9 billion by 2016. Four newly marketed drugs are expected to become part of the Top 20 cancer therapy brands during the forecast period and are set to increase the 2016 sales of the existing Top 20 cancer therapy brands to $52.7 billion.

Scope of this report

Overview of the current Top 20 cancer therapy brands market

Individual country, 5EU and seven-market sales forecasts from 2006 to 2016 for the leading cancer therapy brands

Segmentation and analysis of market dynamics by country sales, drug class, indication, company and impacted events

Detailed product profiles and discussion of assumptions and events used in forecast analysis

Research and analysis highlights

Four newly marketed drugs are expected to become part of the Top 20 cancer therapies during the forecast period: Sutent (sunitinib; Pfizer), Nexavar (sorafenib; Onyx/Bayer), Vectibix (panitumumab; Amgen) and Tykerb (lapatinib; GSK). These products combined with the existing Top 20 cancer therapies are set to reach $52.7 billion in sales by 2016.

The Top 20 cancer therapy brands are forecast to experience 144 different events between 2007 and 2016. Considering the fact that many of these events will take place in each of the seven major markets, Datamonitor expects the Top 20 cancer therapy brands to experience 792 events across the 7MM.

The 35 drugs that make up the Top 20 cancer therapy brands have gained approval in 18 different tumor types. Three of the 'big four' tumor types boast the highest number of leading cancer therapy brands namely: breast cancer with 18 of the 35 forecasted drugs, non-small cell lung cancer with eight, and colorectal cancer with seven.

Key reasons to read this report

Understand market specific drivers and predict the future potential of key cancer therapy brands

Quantify the impact of key patent expiries and product launches and gain a valuable insight into the market dynamics

Consider, assess and react to opportunities and risks influencing the leading cancer therapy brands

Published: 2 July 2007

PDF Format
Table of Contents
Price: $15,200.00 / GBP8,360.00